Axsome Therapeutics (NASDAQ:AXSM) Given “Outperform” Rating at William Blair

Axsome Therapeutics (NASDAQ:AXSM)‘s stock had its “outperform” rating restated by analysts at William Blair in a research note issued to investors on Tuesday,RTT News reports.

A number of other research firms also recently issued reports on AXSM. Truist Financial boosted their price objective on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Bank of America boosted their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft assumed coverage on Axsome Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $176.00 price objective on the stock. Mizuho upped their target price on Axsome Therapeutics from $137.00 to $195.00 and gave the company an “outperform” rating in a research report on Tuesday, February 11th. Finally, Robert W. Baird raised their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $154.80.

Axsome Therapeutics Trading Down 0.9 %

Shares of AXSM stock opened at $126.96 on Tuesday. The company has a market capitalization of $6.15 billion, a PE ratio of -19.44 and a beta of 1.05. The firm has a 50 day moving average price of $99.64 and a two-hundred day moving average price of $94.22. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $134.18.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The firm had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. As a group, analysts predict that Axsome Therapeutics will post -4.59 earnings per share for the current year.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 22.40% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in Axsome Therapeutics in the fourth quarter valued at about $86,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $2,853,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Axsome Therapeutics by 20.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company’s stock valued at $4,877,000 after buying an additional 9,928 shares during the last quarter. Woodline Partners LP boosted its position in Axsome Therapeutics by 36.8% during the 4th quarter. Woodline Partners LP now owns 408,441 shares of the company’s stock worth $34,558,000 after buying an additional 109,872 shares during the period. Finally, Two Sigma Advisers LP grew its holdings in Axsome Therapeutics by 85.3% during the 4th quarter. Two Sigma Advisers LP now owns 6,300 shares of the company’s stock worth $533,000 after acquiring an additional 2,900 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.